Pharm 101: Irbesartan

Class

Angiotensin-II Receptor Bloker

Pharmacodynamics
  • Competitive selective antagonist of angiotensin II type 1 (AT1) receptor
  • Causes vasodilation and inhibition of aldosterone secretion
  • More selective blockers of angiotensin effects than ACE-I, benefits include:
    • More complete inhibition of angiotensin action, because there are enzymes other than ACE capable of generating angiotensin II
    • No effect on bradykinin metabolism so reduced incidence of cough, angioedema
Pharmacokinetics
  • 90% protein bound
  • Half-life 12 hours
  • Liver metabolism
Clinical uses
  • Hypertension
  • CCF
  • Chronic renal failure:
    • Diminish proteinuria and stabilise renal function (even in absence of lowering BP)
Adverse effects
  • Similiar to those of ACE-inhibitors, except for cough and angioedema which are uncommon
Precautions/contraindications
  • Non-diabetic renal failure
  • Pregnancy
  • Hyperkalaemia
  • Renal artery stenosis
Further Reading
Pharm 101 700

Pharmacology 101

Top 200 drugs

MBBS CCPU (RCE, Biliary, DVT, E-FAST, AAA) Rob is an Emergency Medicine Advanced Trainee based in Melbourne, Australia. He has special interests in medical education, ECG interpretation, and the use of diagnostic and procedural ultrasound in the undifferentiated and unwell patient.

Follow him on twitter: @rob_buttner | ECG Library |

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.